Your partner for 760+ high-quality medicines.

All across the United States, people lean on us to deliver high-quality medicines that put better health within reach every day. We develop, manufacture and distribute a broad range of injectable, oral, nasal and inhalable generic and branded pharmaceutical products, including essential medicines that hospitals, physicians and pharmacists need to treat their patients.

US hospitals and Hikma

How our partners have leaned on us.

Hikma continues to play a major role in helping US hospitals and healthcare systems alleviate shortages of essential medicines.

Fighting the opioid epidemic

How our partners have leaned on us.
Hikma produces life-saving medicines to help address the opioid epidemic in the US.

Helping fight the opioid pandemic with Gibson Gives TEMPO Program

How our partners have leaned on us.
Hikma has partnered with non-profit and community organizations, including the Gibson Gives TEMPO Program, to help fight the opioid epidemic in the US.

Contract manufacturing offerings

How our partners have leaned on us.

A detailed look at how Hikma has brought its global manufacturing prowess to Columbus, Ohio, US and to its sterile injectable sites in Europe and in the US.

Seasonal allergy relief is here

How allergists lean on us.
Allergists can lean on Hikma to help treat millions of people in the US suffering from seasonal allergies.

How our communities Lean on Us

How our partners have leaned on us.
Transforming lives and communities through addiction therapy and personalized service to health and community organizations nationwide.

Helping families fight the overdose epidemic

How our partners have leaned on us.
Hikma's partner organization takes over Times Square and distributes lifesaving medicine to help raise awareness about the opioid epidemic in the US.

How our partners have leaned on us.

Our Columbus, Ohio facility hosts White House Office of National Drug Control Policy Director Dr. Rahul Gupta, “Expanding access to overdose reversal medication like naloxone is a key priority...”

Solving shortages

How our partners have leaned on us.
Hospitals partner with Hikma 503B for the essential compounded sterile injectable medicines they need.

Saving lives

How our partners have leaned on us

U.S. Congressman organizes community training event on how to use Naloxone.

Our injectable medicines

As one of the largest manufacturers by volume of sterile injectable medicines in the US, we serve the growing needs of thousands of hospitals and millions of patients, including through our Hikma 503B compounded sterile injectable products for hospitals.

Discover more

Oral, nasal and other non-injectable products

Our ever-growing pipeline of oral, nasal, and inhalable generic and specialty-branded medicines in the US helps us deliver a wide-range of essential products our customers rely upon.

Oral Nasal Generics
Discover more

Our specialty products

Our highly experienced pharmaceutical team develops, creates, manufactures and markets branded generics and in-licensed products across the US, and our portfolio continues to diversify.

Visit Hikma Speciality

Our CMO capabilities for oral and other non-injectable

Discover our world-class 360° pharmaceutical contract manufacturing (CMO) capabilities across a broad range of oral and non injectable dosage forms, best-in-class production facilities, and excellent quality track record.

Contract manufacturing for oral & nasal

Hikma 503B

We provide compounded sterile injectables for the US. We have a proven track record of cGMP in sterile drug manufacturing. We have extensive access to raw materials and established relationships with our hospital customers and we are FDA approved.

Discover more about 503B
Decorative image.
Decorative image.
Decorative image.
Decorative image.
Decorative image.
Hikma US highlights
2 R&D hubs
2,165 Employees
4 Manufacturing plants

Useful links

Last reviewed: July 1, 2024

Policies that regulate Hikma colleagues' interactions with health care professionals in the United States reflect our commitment to compliance with applicable federal and state laws and regulations. We review and revise our policies as we deem appropriate to meet the requirements of a highly regulated and complex health care environment. California SB 1765 (California Business & Professions Code 119400, 119402) requires pharmaceutical companies to set an annual aggregate limit on certain promotional expenditures provided to a medical or health care professional as defined under the statute. Hikma has determined that the annual aggregate limit on covered promotional expenditures is set at $1,500 per covered medical or health care professional. This limit may be revised by Hikma from time to time. The foregoing limit does not represent a usual, customary, average, or typical amount for medical or health care professionals.

The statute excludes covered promotional expenditures, such items as drug samples given to medical or health care professionals intended for free distribution to patients, financial support for continuing medical education forums, financial support for health educational scholarships, and payments made at fair market value for legitimate professional services provided by health care professionals.

This annual aggregate limit is based on an estimate of the maximum value of hospitality, promotional materials, and other items of value as defined herein that a medical or health care professional may receive in a year. In setting this limit, we have taken into account the size of the Company and the size of its product portfolio.

The US site

The information provided in this site is intended for US audiences only. Always consult a healthcare professional for medical advice. Hikma is not responsible for any access to materials which are not intended for US audiences.